Alpha Tau Medical (DRTSW) Capital Expenditures (2021 - 2022)

Alpha Tau Medical (DRTSW) posted Capital Expenditures of -$377000.0 for Q2 2022, down 26.51% sequentially from -$298000.0 in Q1 2022.

Alpha Tau Medical (DRTSW) Capital Expenditures (2021 - 2022) Analysis & Trends

Alpha Tau Medical has reported Capital Expenditures for 2 years, with the latest figure at -$377000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.79 Bn	131.94 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.74 Bn	78.74 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.48 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	59.32 Bn	54.18 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.81 Bn	28.50 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.56 Bn	26.40 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	251.02 Mn
10	Alpha Tau Medical	362.22 Mn	179.81 Mn	-	-

Download Data